ArticleClinical kidney journal2026
Achieved systolic blood pressure and cardiovascular outcomes in advanced chronic kidney disease.
Article in Clinical kidney journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In advanced chronic kidney disease (CKD) evidence for lower systolic blood pressure (SBP) targets is limited and guideline recommendations are conflicting. We investigated the association between achieved SBP and major adverse cardiovascular events (MACE) in nephrology-referred patients with CKD. Methods: In this nationwide, observational cohort from the Swedish Renal Register-chronic kidney disease (SRR-CKD), we included adults with CKD stages 3-5 referred to nephrology outpatient clinics between 2006 and 2017. Mean office SBP during the first year was categorized in incrementally higher SBP groups with 130-<140 mmHg as reference. The primary outcome was MACE; secondary outcomes were its components and all-cause death, analyzed using cause-specific multivariable-adjusted flexible parametric survival models. Results: Among 23 317 patients (median age 72 years; 64% men; median estimated glomerular filteration rate (eGFR) 24 ml/min/1.73 m²), over a median follow-up of 2.5 years, 8556 (37%) experienced MACE and 7686 (33%) died. Compared with SBP 130-<140 mmHg, SBP 120-<130 mmHg was associated with lower risks of MACE [adjusted hazard ratio (HR) 0.93, 95% confidence interval (CI) 0.87-0.99] and all-cause mortality (HR 0.93, 95% CI 0.87-0.99), whereas SBP ≥160 mmHg was associated with higher risks of MACE (HR 1.38, 95% CI 1.28-1.49) and death (HR 1.29, 95% CI 1.20-1.38). MACE risk was nonproportional and declined over time in patients with SBP 100-<120 mmHg, demonstrating lower MACE risk compared to 130-<140 after 3 years. In continuous analyses, MACE risk was lowest around 125 mmHg and increased at higher SBP levels. Conclusions: In nephrology-referred patients with advanced CKD, achieved SBP around 120-<130 mmHg (near 125 mmHg) was associated with the lowest cardiovascular and mortality risk, while SBP ≥140 mmHg, especially ≥160 mmHg, was consistently associated with higher MACE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.